Shekhtman Oleg, Sioutas Georgios S, Dagli Mert Marcel, Matache Irina-Mihaela, Pukenas Bryan A, Jankowitz Brian T, Burkhardt Jan-Karl, Srinivasan Visish M
Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Physiology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Interv Neuroradiol. 2024 Aug 8:15910199241272515. doi: 10.1177/15910199241272515.
Robotic neurointervention enhances procedural precision, reduces radiation risk, and improves care access. Originally for interventional cardiology, the CorPath GRX platform has been used in neurointerventions. Recent studies highlight robotic cerebral angiography benefits, but information on spinal angiography is limited. While a new generation of robotic solutions is on the horizon, this series evaluates our experience with the CorPath GRX in spinal angiographic procedures, addressing a key gap in neurointerventional research.
In this single-center retrospective case series, we analyzed 11 patients who underwent robotic-assisted diagnostic procedures with the CorPath GRX system from February 2022 to March 2023 at our institution. A descriptive synthesis was performed on the demographic, baseline, surgical, and postoperative data collected.
The average age of the 11 patients was 54 ± 20.34 years, with six (54.55%) female. The mean body mass index was 29.58 ± 7.86, and 7 (63.64%) were non-smokers. Of the 11 procedures using the CorPath GRX system, four (36.36%) were partially converted to manual technique. General anesthesia was used in nine cases (81.82%), and right-side femoral access in ten (90.91%) patients. Mean fluoroscopy time was 24.81 ± 10.19 min, contrast dose 174.09 ± 57.31 mL, dose area product 472.23 ± 437.57 Gy·cm², and air kerma 2438.84 ± 2107.06 mGy. No robot-related complications and minimal procedure-related complications were reported.
The CorPath GRX system, a robotic-assisted platform, has proven reliable and safe in spinal angiography, evidenced by its enhanced procedural accuracy and reduced radiation exposure for operators.
机器人神经介入技术可提高手术精度，降低辐射风险，并改善医疗服务可及性。CorPath GRX平台最初用于介入心脏病学，现已应用于神经介入手术。近期研究凸显了机器人脑血管造影的优势，但关于脊髓血管造影的信息有限。尽管新一代机器人解决方案即将问世，但本系列研究评估了我们在脊髓血管造影手术中使用CorPath GRX的经验，填补了神经介入研究中的一个关键空白。
在这个单中心回顾性病例系列中，我们分析了2022年2月至2023年3月在我院接受CorPath GRX系统机器人辅助诊断手术的11例患者。对收集到的人口统计学、基线、手术和术后数据进行了描述性综合分析。
11例患者的平均年龄为54±20.34岁，其中6例（54.55%）为女性。平均体重指数为29.58±7.86，7例（63.64%）为非吸烟者。在使用CorPath GRX系统的11例手术中，4例（36.36%）部分转为手动技术。9例（81.82%）采用全身麻醉，10例（90.91%）患者经右侧股动脉穿刺。平均透视时间为24.81±10.19分钟，造影剂用量为174.09±57.31毫升，剂量面积乘积为472.23±437.57 Gy·cm²，空气比释动能为2438.84±2107.06 mGy。未报告与机器人相关的并发症，手术相关并发症也极少。
CorPath GRX系统作为一种机器人辅助平台，在脊髓血管造影中已被证明可靠且安全，其提高了手术准确性并减少了术者的辐射暴露。
